Accueil>>Signaling Pathways>> Metabolism>> Metabolic Syndrome>>sPLA2 Inhibitor

sPLA2 Inhibitor (Synonyms: KH064, Secretory Phospholipase A2 Inhibitor)

Catalog No.GC44943

L'inhibiteur de sPLA2, un dérivé de la D-tyrosine, est un puissant inhibiteur sécrétoire de la phospholipase A2 (sPLA2) actif par voie orale avec une IC50 de 29 nM pour l'isoforme de PLA2 sécrétoire non pancréatique humaine IIa (hnpsPLA2-IIa).

Products are for research use only. Not for human use. We do not sell to patients.

sPLA2 Inhibitor Chemical Structure

Cas No.: 393569-31-8

Taille Prix Stock Qté
500μg
60,00 $US
En stock
1mg
103,00 $US
En stock
5mg
419,00 $US
En stock
10mg
756,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Secreted phospholipases A2 (sPLA2s) are a diverse family of low molecular weight PLA2s with tissue-specific expression patterns and actions. The group IIA sPLA2 (sPLA2-IIA) was originally purified from platelets and exudates from patients with rheumatoid arthritis. Its expression can be induced by inflammatory mediators, and mouse studies suggest that it may play roles in colorectal polyposis, atherosclerosis, and bacterial infections. sPLA2 inhibitor is an orally active inhibitor of sPLA2-IIA. It protects against intestinal reperfusion injury in rats when given at 10 mg/kg orally. sPLA2 inhibitor also attenuates NF-κB signaling in lung cancer cells and protects against diet-induced metabolic syndrome in rats.

Avis

Review for sPLA2 Inhibitor

Average Rating: 5 ★★★★★ (Based on Reviews and 7 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for sPLA2 Inhibitor

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.